Iovance reports ~$317M cash as of June 30; authorized shares increased to 500M

IOVANCE BIOTHERAPEUTICS, INC.

Preliminary cash, equivalents, short-term investments, and restricted cash ~$317M as of June 30, 2023 (unaudited).
Stockholders approved increase in authorized common stock from 300M to 500M at June 6 annual meeting; certificate filed June 9.
The cash estimate is subject to change upon completion of quarter-end closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.